Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

    Get Diamond plan for FREE

    logo

    MiMedx Group, Inc. (MDXG)

    Price:

    7.31 USD

    ( + 0.28 USD)

    Your position:

    0 USD

    ACTION PANEL
    CREATE A NOTE
    ABOUT
    Symbol
    MDXG
    Name
    MiMedx Group, Inc.
    Industry
    Biotechnology
    Sector
    Healthcare
    Price
    7.310
    Market Cap
    1.082B
    Enterprise value
    1.334B
    Currency
    USD
    Ceo
    Joseph H. Capper
    Full Time Employees
    837
    Website
    Ipo Date
    2008-02-12
    City
    Marietta
    Address
    1775 West Oak Commons Court, NE

    Check the

    KEY TAKEAWAYS

    ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)
    Descriptive alt text

    (REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION

    SIMILAR COMPANIES STI SCORE

    Similar STI Score

    Regeneron Pharmaceuticals, Inc.

    VALUE SCORE:

    6

    Symbol
    REGN
    Market Cap
    61.406B
    Industry
    Biotechnology
    Sector
    Healthcare

    2nd position

    Genmab A/S

    VALUE SCORE:

    11

    Symbol
    GMAB
    Market Cap
    99.053B
    Industry
    Biotechnology
    Sector
    Healthcare

    The best

    Agios Pharmaceuticals, Inc.

    VALUE SCORE:

    12

    Symbol
    AGIO
    Market Cap
    2.254B
    Industry
    Biotechnology
    Sector
    Healthcare
    FUNDAMENTALS
    P/E
    33.572
    P/S
    2.973
    P/B
    4.986
    Debt/Equity
    0.085
    EV/FCF
    15.995
    Price to operating cash flow
    -1.000
    Price to free cash flow
    -1.000
    EV/sales
    2.697
    Earnings yield
    0.030
    Debt/assets
    0.063
    FUNDAMENTALS
    Net debt/ebidta
    -2.016
    Interest coverage
    14.246
    Research And Developement To Revenue
    0.036
    Intangile to total assets
    0.108
    Capex to operating cash flow
    0.020
    Capex to revenue
    0.003
    Capex to depreciation
    0.150
    Return on tangible assets
    0.124
    Debt to market cap
    0.017
    Piotroski Score
    6.000
    FUNDAMENTALS
    PEG
    -1.880
    P/CF
    17.956
    P/FCF
    17.632
    RoA %
    11.052
    RoIC %
    12.769
    Gross Profit Margin %
    81.453
    Quick Ratio
    3.897
    Current Ratio
    4.392
    Net Profit Margin %
    8.845
    Net-Net
    0.736
    FUNDAMENTALS PER SHARE
    FCF per share
    0.415
    Revenue per share
    2.462
    Net income per share
    0.218
    Operating cash flow per share
    0.407
    Free cash flow per share
    0.415
    Cash per share
    0.804
    Book value per share
    1.466
    Tangible book value per share
    1.253
    Shareholders equity per share
    1.466
    Interest debt per share
    0.145
    TECHNICAL
    52 weeks high
    10.140
    52 weeks low
    5.470
    Current trading session High
    7.390
    Current trading session Low
    7.090
    DIVIDEND
    Dividend yield
    0.00%
    Payout ratio
    0.00%
    Years of div. Increase
    0
    Years of div.
    0
    Q-shift
    Dividend per share
    0
    SIMILAR COMPANIES
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Medical - Devices
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -159.027
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.046
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -10.341
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    16.391
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -4.720
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.480
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.931
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -0.521
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    -2.105
    logo

    Country
    US
    Sector
    Healthcare
    Industry
    Biotechnology
    Dividend yield
    0%
    Payout Ratio
    0%
    P/E
    70.153
    DESCRIPTION

    MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. It processes the human placental tissues utilizing its patented and proprietary PURION process to produce allografts that retains the tissue's inherent biological properties and regulatory proteins. The company's patented and proprietary processing method employs aseptic processing techniques in addition to terminal sterilization. Its products include EpiFix, a semi-permeable protective barrier membrane product used for the treatment of chronic wounds, including diabetic foot ulcers, venous leg ulcers, and pressure ulcers; AmnioFix, a semi-permeable protective barrier allograft, which comprises dehydrated human amnion/chorion membrane for use in surgical recovery applications; EpiCord and AmnioCord are dehydrated human umbilical cord allografts that are used to provide a protective environment for the healing process, as well as used in the advanced wound care and surgical recovery applications; and AMNIOBURN a semi-permeable protective barrier allograft used in the treatment of partial-thickness and full-thickness burns, as well as lead product includes mdHACM, a micronized form of AMNIOFIX, supplied in powder form. The company's products have applications primarily in the areas of wound care, burn, surgical, and non-operative sports medicine sectors of healthcare. It also sells allografts for dental applications on an original equipment manufacturer basis. The company sells its products through direct sales force and independent sales agents, as well as through independent distributors primarily in the United States. MiMedx Group, Inc. is headquartered in Marietta, Georgia.

    NEWS
    https://images.financialmodelingprep.com/news/mimedx-group-inc-mdxg-q2-2025-earnings-call-transcript-20250730.jpg
    MiMedx Group, Inc. (MDXG) Q2 2025 Earnings Call Transcript

    seekingalpha.com

    2025-07-30 23:01:44

    MiMedx Group, Inc. (NASDAQ:MDXG ) Q2 2025 Earnings Conference Call July 30, 2025 4:30 PM ET Company Participants Douglas C. Rice - Chief Financial Officer Joseph H.

    https://images.financialmodelingprep.com/news/mimedx-mdxg-q2-earnings-and-revenues-beat-estimates-20250730.jpg
    MiMedx (MDXG) Q2 Earnings and Revenues Beat Estimates

    zacks.com

    2025-07-30 18:41:07

    MiMedx (MDXG) came out with quarterly earnings of $0.1 per share, beating the Zacks Consensus Estimate of $0.06 per share. This compares to earnings of $0.08 per share a year ago.

    https://images.financialmodelingprep.com/news/mimedx-announces-record-second-quarter-2025-operating-and-financial-20250730.jpg
    MIMEDX Announces Record Second Quarter 2025 Operating and Financial Results

    globenewswire.com

    2025-07-30 16:01:00

    Highest Quarterly Net Sales in MIMEDX History Second Quarter Net Sales of $99 million Grew 13% Year-Over-Year  Second Quarter GAAP Net Income and Diluted Earnings Per Share were $10 Million and $0.06, Respectively Second Quarter Adjusted EBITDA was $24 Million, or 25% of Net Sales Raises 2025 Net Sales Growth Expectations Management to Host Conference Call Today, July 30, 2025 , at 4:30 PM ET MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the second quarter 2025.

    https://images.financialmodelingprep.com/news/mimedx-announces-strategic-collaboration-with-vaporox-inc-20250730.jpg
    MIMEDX Announces Strategic Collaboration with Vaporox, Inc.

    globenewswire.com

    2025-07-30 08:00:00

    MARIETTA, Ga., July 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) and Vaporox, Inc. (“Vaporox”) today jointly announced a collaboration, whereby the companies will co-promote and co-market their wound care offerings.

    https://images.financialmodelingprep.com/news/mimedx-to-host-second-quarter-2025-operating-and-financial-20250716.jpg
    MIMEDX to Host Second Quarter 2025 Operating and Financial Results Conference Call on July 30

    globenewswire.com

    2025-07-16 08:00:00

    MARIETTA, Ga., July 16, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will report its operating and financial results for the second quarter ended June 30, 2025 after the market close on Wednesday, July 30, 2025.

    https://images.financialmodelingprep.com/news/mimedx-comments-on-proposed-medicare-reimbursement-rule-changes-for-cy-20250715.jpg
    MIMEDX Comments on Proposed Medicare Reimbursement Rule Changes for CY 2026

    globenewswire.com

    2025-07-15 09:15:00

    New Mechanism for the Reimbursement of Skin Substitutes Aimed at Curbing Fraud, Waste and Abuse New Mechanism for the Reimbursement of Skin Substitutes Aimed at Curbing Fraud, Waste and Abuse

    https://images.financialmodelingprep.com/news/strength-seen-in-mimedx-mdxg-can-its-80-jump-20250709.jpg
    Strength Seen in MiMedx (MDXG): Can Its 8.0% Jump Turn into More Strength?

    zacks.com

    2025-07-09 10:42:10

    MiMedx (MDXG) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

    https://images.financialmodelingprep.com/news/mimedx-to-participate-in-upcoming-investor-conferences-20250527.jpg
    MIMEDX to Participate in Upcoming Investor Conferences

    globenewswire.com

    2025-05-27 08:00:00

    MARIETTA, Ga., May 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the following investor conferences: Craig-Hallum 22 nd Annual Institutional Investor Conference | Minneapolis, MN 1:1 sessions: Wednesday, May 28, 2025 Goldman Sachs 46 th Annual Global Healthcare Conference | Miami, FL 1:1 sessions: Wednesday, June 11, 2025 Northland Capital Growth Conference | Virtual 1:1 sessions: Wednesday, June 25, 2025 Investors interested in meeting with senior management at these events may contact their respective Craig-Hallum, Goldman Sachs or Northland representative.

    https://images.financialmodelingprep.com/news/mimedx-to-present-at-the-bofa-securities-2025-healthcare-20250506.jpg
    MIMEDX to Present at the BofA Securities 2025 Healthcare Conference

    globenewswire.com

    2025-05-06 08:00:00

    MARIETTA, Ga., May 06, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that members of its senior management will participate in the BofA Securities 2025 Healthcare Conference in Las Vegas, NV.

    https://images.financialmodelingprep.com/news/mimedx-announces-publication-of-health-economics-data-in-mohs-20250505.jpg
    MIMEDX Announces Publication of Health Economics Data in Mohs Micrographic Surgery (MMS)

    globenewswire.com

    2025-05-05 08:30:00

    Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company's EPIFIX® Placental Allograft Product Propensity Score-Matched, Comparative Cost-Effectiveness Analysis of the Company's EPIFIX® Placental Allograft Product

    https://images.financialmodelingprep.com/news/mimedx-group-inc-mdxg-q1-2025-earnings-call-transcript-20250430.jpg
    MiMedx Group, Inc. (MDXG) Q1 2025 Earnings Call Transcript

    seekingalpha.com

    2025-04-30 21:52:10

    MiMedx Group, Inc. (NASDAQ:MDXG ) Q1 2025 Earnings Conference Call April 30, 2025 4:30 PM ET Company Participants Matthew Notarianni - Head, IR Joseph Capper - CEO & Director Doug Rice - CFO Conference Call Participants Carl Byrnes - Northland Capital Markets Chase Knickerbocker - Craig-Hallum Capital Group Ross Osborn - Cantor Fitzgerald Anthony Petrone - Mizuho Group Operator Good afternoon, and thank you for standing by. Welcome to the MIMEDX First Quarter 2025 Operating and Financial Results Conference Call.

    https://images.financialmodelingprep.com/news/mimedx-mdxg-q1-earnings-match-estimates-20250430.jpg
    MiMedx (MDXG) Q1 Earnings Match Estimates

    zacks.com

    2025-04-30 18:15:31

    MiMedx (MDXG) came out with quarterly earnings of $0.06 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.07 per share a year ago.

    https://images.financialmodelingprep.com/news/mimedx-announces-first-quarter-2025-operating-and-financial-results-20250430.jpg
    MIMEDX Announces First Quarter 2025 Operating and Financial Results

    globenewswire.com

    2025-04-30 16:01:00

    Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA was $17 Million, or 20% of Net Sales Reaffirms Expected 2025 Net Sales Growth Expectations Management to Host Conference Call Today, April 30, 2025 , at 4:30 PM ET MARIETTA, Ga., April 30, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”), today announced operating and financial results for the first quarter 2025.

    https://images.financialmodelingprep.com/news/mimedx-to-feature-growing-body-of-clinical-and-scientific-20250410.jpg
    MIMEDX to Feature Growing Body of Clinical and Scientific Evidence at Upcoming Wound & Surgical-Focused Industry Conferences

    globenewswire.com

    2025-04-10 16:01:00

    MARIETTA, Ga., April 10, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that it will participate in the following industry conferences this quarter to feature the latest scientific and clinical data supporting the use of its portfolio of Advanced Wound Care and Surgical Solutions.

    https://images.financialmodelingprep.com/news/mimedx-to-present-at-td-cowen-45th-annual-health-20250227.jpg
    MIMEDX to Present at TD Cowen 45th Annual Health Care Conference

    globenewswire.com

    2025-02-27 08:00:00

    MARIETTA, Ga., Feb. 27, 2025 (GLOBE NEWSWIRE) -- MiMedx Group, Inc. (Nasdaq: MDXG) (“MIMEDX” or the “Company”) today announced that senior management will participate in the TD Cowen 45th Annual Health Care Conference.

    https://images.financialmodelingprep.com/news/mimedx-group-inc-mdxg-q4-2024-earnings-call-transcript-20250226.jpg
    MiMedx Group, Inc. (MDXG) Q4 2024 Earnings Call Transcript

    seekingalpha.com

    2025-02-26 22:50:46

    MiMedx Group, Inc. (NASDAQ:MDXG ) Q4 2024 Earnings Conference Call February 26, 2024 4:30 AM ET Company Participants Matt Notarianni - Head, Investor Relations Joseph Capper - Chief Executive Officer Doug Rice - Chief Financial Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Group Ross Osborn - Cantor Fitzgerald Bradley Bowers - Mizuho Securities Brooks O'Neil - Lake Street Capital Markets Carl Byrnes - Northland Capital Markets Operator Good afternoon, and thank you for standing by. Welcome to the MiMedx Fourth Quarter and Full Year 2024 Operating Financial Results Conference Call.